降钙素基因相关肽拮抗剂治疗偏头痛相关的肺动脉高压:病例系列
本文报告3例在接受降钙素基因相关肽(CGRP)靶向治疗期间经血流动力学确诊的肺动脉高压(PAH)患者,其中2例无传统PAH危险因素,1例疑似门静脉高压。所有患者肺血管阻力显著升高,2例在停用CGRP靶向治疗并启动PAH治疗后改善。作者认为时间关联与生物学合理性提示潜在安全信号,需进一步研究。
要点
- 接受CGRP靶向治疗者出现心肺症状时应警惕PAH可能
- 3例均肺血管阻力显著升高,2例停药并治疗PAH后改善
- 因果关系尚不能确定,但提示需系统研究其心肺风险
核心结论
- CGRP靶向治疗与PAH存在时间关联和生物学合理性,构成潜在安全信号,但尚不能推断因果关系。
研究设计与样本
- 病例系列,报告3例在接受CGRP靶向治疗期间经血流动力学确诊PAH的患者。
主要发现
- 2例缺乏传统PAH危险因素,第3例疑似门静脉高压。
- 所有患者肺血管阻力显著升高。
- 2例在停用CGRP靶向治疗并启动PAH治疗后改善。
关键数值与推荐
- CGRP单克隆抗体2018年上市、gepants于2020年上市,现广泛用于偏头痛预防和急性治疗。
- CGRP是强效内源性肺血管扩张剂,实验模型中其阻断可加重肺动脉高压。
临床怎么用
- 对接受CGRP靶向治疗的偏头痛患者,应关注心肺症状并警惕PAH可能。
局限性
- 病例数仅3例,无法推断因果关系。
- 人类CGRP通路抑制的心肺风险尚未被系统研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Calcitonin gene-related peptide (CGRP)-targeted therapies are a recent addition to the migraine field. Monoclonal antibodies became available in 2018 and gepants in 2020, both now widely used for migraine prevention and acute treatment. CGRP is also a potent endogenous pulmonary vasodilator, and its blockade worsens pulmonary hypertension in experimental models. Yet the cardiopulmonary risks of CGRP pathway inhibition in humans have not been studied systematically. We report 3 patients with hemodynamically confirmed pulmonary arterial hypertension (PAH) diagnosed while they were receiving CGRP-targeted therapy. Two patients lacked traditional PAH risk factors; the third patient had suspected portal hypertension. All patients presented with markedly elevated pulmonary vascular resistance, and 2 patients improved after CGRP-targeted therapy was discontinued and PAH treatment was initiated. Although causality cannot be inferred from these cases, the temporal association and biologic plausibility suggest a potential safety signal deserving of further study. Clinicians should remain vigilant for cardiopulmonary symptoms in patients receiving CGRP-targeted therapies.
引用
- Lu K, Barros LM, Murinova N, et al. Pulmonary Arterial Hypertension Associated With Calcitonin Gene-Related Peptide Antagonist Therapy for Migraine: A Case Series. Chest. 2026. PMID: 42264575. doi:10.1016/j.chest.2025.12.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。